Sanofi (SNY) EPS (Basic) (2009 - 2026)

Sanofi (SNY) posted EPS (Basic) of -$6.35 for Q2 2026, down 504.67% sequentially from $1.57 in Q1 2026, and down 274.48% YoY from $3.64 in Q2 2025.

Sanofi (SNY) EPS (Basic) (2009 - 2026) Analysis & Trends

Sanofi has reported EPS (Basic) for 18 years, with the latest figure at -$6.35 in Q2 2026.

Quarterly EPS (Basic) fell 274.48% year-over-year to -$6.35 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$2.79 (down 133.99% YoY) and the FY2025 annual result came in at $7.45, up 56.96% from the prior year.
EPS (Basic) declined to -$6.35 in Q2 2026 per SNY's latest filing, from $1.57 in the prior quarter.
Over five years, EPS (Basic) peaked at $8.23 in Q3 2025 and troughed at -$6.35 in Q2 2026.
A 5-year average of $1.15 and a median of $1.58 in 2026 frame the typical range for EPS (Basic).
The widest YoY moves for EPS (Basic): up 279.36% in 2025, down 1580.29% in 2025.
Over 5 years, EPS (Basic) stood at $4.29 in 2022, then plunged by 111.13% to -$0.48 in 2023, then jumped by 189.32% to $0.43 in 2024, then plunged by 1580.29% to -$6.31 in 2025, then dropped by 0.67% to -$6.35 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$6.35, $1.57, and -$6.31 for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	2.30
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	2.04
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	-0.54
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	1.71
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	1.62
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	4.40
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	-8.44
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	-0.04
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	0.29
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	0.33

Download Data